US/UK/Canada

Share

About Us

Phase Holographic Imaging (PHI) develops and markets instrumentation for non-invasive time-lapse imaging. The company’s HoloMonitor product line is used for long-term quantitative analysis of living cell cultures, particularly in preclinical research and regenerative medicine. PHI is based in Lund, Sweden and Boston, Massachusetts.

Contacts

  • Patrik Eschricht

    CEO


    Skiffervägen 48, 224 78, Lund
    http://www.phiab.com

    • Links

    Quotes

    When we looked at PHI technology, we got impressed. And when we saw whom PHI partners with, the Wake Forest Institute for Regenerative Medicine, BioSpherix and global analytics company SAS, the investment decision was very easy. Here we have a company that will be part of the future of medicine
    Goran Dubravcic, CEO Altium
    Pick a time period -
    Tags ( Active)

    Adopting the final Annual Report

    PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.It has come to the attention of Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company") that the annual report for the fiscal year 2023/2024 that was made available and presented at the annual general meeting held on 31 October 2024 was not the final and audited version. Furthermore, Leland Foster has declined to be reelected to the board. The correct and audited annual report for the fiscal

    PHI's new CEO to BioStock: "I am excited to lead us forward with new energy"

    Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. We spoke with him about his vision for the future.Read the full interview with Anders Månsson at biostock.se: https://www.biostock.se/en/2024/11/phis-new-ceo-i-am-excited-to-lead-us-forward-with-new-energy/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

    Phase Holographic Imaging PHI AB (publ), reg.no 556542-7811 (the “Company”) held its annual general meeting on 31 October 2024. The following resolutions were made.Adoption of the income statement and balance sheet The annual general meeting resolved to adopt the board of directors’ proposal for the income statement and the balance sheet for the fiscal year of 2023/24. Disposition of the Company’s profit or loss The annual general meeting resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid and that the result for the year is carried forward.

    PHI secures a loan from Altium SA

    Phase Holographic Imaging PHI AB ("PHI") announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.Altium SA has provided PHI with a loan of SEK 7 million, granting PHI funds to repay a previous loan raised from Bizcap AB earlier this year. The loan has an interest rate of 1.5 percent per month, and a maturity date on the 30[th] of June 2025. PHI can repay the loan and interest at any time before the maturity date. The Board of Directors of PHI and Altium SA, as

    PHI AB’s warrant exercise registered at the Swedish Companies Registration Office

    Phase Holographic Imaging PHI AB ("PHI" or "Company") today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with PHI’s rights issue of units in 2022, ended. As a result of the warrant exercise, 1,129,513 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 4 amounts to 27,322,438 and

    PHI appoints Anders Månsson as new CEO

    The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson."I and the board are very pleased to welcome Anders as the new CEO of PHI. His solid background and experience in the life science industry is a strong asset to us. I would also like to extend a warm thank you to Patrik for his time as CEO. Under Patrik’s leadership, the company has expanded its market share and deepened collaborations

    Phase Holographic Imaging PHI AB receives approx. SEK 5.2 million through warrant exercise

    On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s ("PHI" or the “Company") rights issue of units in 2022 (“TO 4”), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.Outcome of the exercise of warrants of series TO 4 During the exercise period, 12 september-3 October 2024, holders of TO 4 had the right to subscribe for

    BioStock: PHI accelerates growth with record order

    Phase Holographic Imaging recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.Read the full interview with Patrik Eschricht at biostock.se: https://www.biostock.se/en/2024/10/phi-accelerates-growth-with-record-order/ This is a press release

    Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)

    The shareholders of Phase Holographic Imaging PHI AB (publ), reg. nr. 556542-7811, are hereby invited to attend the annual general meeting on the 31 October 2024 at 11.00 at the company´s office at Skiffervägen 48 in Lund.Right to participate and notification Shareholders who wish to participate in the annual general meeting must: · be entered into the share register maintained by Euroclear Sweden AB on 23 October 2024. · give notice to the company no later than 25 October 2024. Notification of participation can be made by e-mail to ir@phiab.se. Notification can also be made

    The last day of trading in warrants of series TO 4 is on 1 October 2024

    The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB's ("PHI" or the "Company") preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.In connection with the Company's preferential rights issue of units carried out in the Spring of 2022, 1,346,162 warrants of series TO 4 were issued. Holders of TO 4 have the right to subscribe for one (1) new share in PHI at a price of SEK 4.63 per share during the exercise period, which runs until 3 October

    PHI announces significant order agreement from Altium for 20 HoloMonitor systems

    Phase Holographic Imaging (PHI) is excited to announce a significant order agreement from Altium for 20 HoloMonitor systems, which will be shipped in the second half of 2024. The order agreement includes systems with various configurations and add-ons, which will impact the total order value."This order agreement from Altium is a testament to their strong confidence in the capability of HoloMonitor and its potential to meet market demands. Our collaboration with Altium has been influenced by an onboarding process and integration of new sales partners, which is starting to pay off as those

    The exercise period for warrants of series TO 4 commences today

    Today is the first day for the exercise of Phase Holographic Imaging PHI AB's ("PHI" or "Company") warrants of series TO 4 ("TO 4") which were issued in connection with the preferential issue of units that the Company carried out during 2022. The period lasts until October 3, 2024. Holders of TO 4 have the right to subscribe for one (1) new share in PHI for each TO 4 at a price of SEK 4.63 per share. Through full use of TO 4, the Company can receive a maximum of approximately SEK 6.2 million before issue costs. An information document is available on the respective websites of PHI (www.phiab.

    The exercise price for warrants of series TO 4 has been set to SEK 4.63 per new share

    Phase Holographic Imaging PHI AB ("PHI" or "the Company") hereby announces that the exercise price for the warrants of series TO 4 (”TO 4”), which were issued in connection with the rights issue of units that the Company executed during 2022, has been set. The exercise price for TO 4 has been set to SEK 4.63 per share and the exercise period commences on September 12, 2024.In the Spring of 2022, PHI carried out a rights issue which brought the Company approximately SEK 57.6 million before issue costs. Through the rights issue, 1,346,162 warrants of series TO 4 were issued. Each TO 4

    Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)

    Phase Holographic Imaging PHI AB (publ) (“PHI” or the “Company”) held an extraordinary general meeting on 2 September 2024. The following resolutions were passed at the meeting.For the period until the next annual general meeting, the extraordinary general meeting resolved to elect John Moore as new ordinary board member. John Moore is an active investor and entrepreneur in the life science and energy industries. He currently serves as Chairman of two public life science companies Nyrada (NYR-ASX) and Scientific Industries (SCND-OTCQB) and two private companies Trialogics, a clinical

    PHI enters the US capital market – shares now also traded on OTCQB

    Phase Holographic Imaging (PHI) is thrilled to announce its official approval for listing on the OTCQB Venture Market in the U.S., with trading commencing yesterday, Thursday, August 15th. This marks an important milestone in expanding our reach and enhancing accessibility for U.S. investors, setting the stage for improved engagement and continued growth.Effective August 15th, PHI has been admitted to trading on the OTCQB under the symbol "PHIXF". OTC Markets Group operates regulated markets for trading U.S. and international securities, offering global companies the opportunity to make

    New date: Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)

    Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the "Company"), will hold an extraordinary general meeting on 2 September at 14.00 at the Company’s premises at Skiffervägen 48 in Lund.Right to participate and notification Shareholders who wish to participate in the general meeting must: ·be recorded as shareholder in the share register prepared by Euroclear Sweden AB regarding the conditions on the record date of 23 August 2024, and ·notify the Company no later than 27 August 2024. Notification can be made in writing to Phase Holographic Imaging PHI AB,

    PHI postpones the extraordinary general meeting until September 2, 2024

    The Board of Directors of Phase Holographic Imaging PHI AB (publ) (the "Company"), has decided to postpone the date of the extraordinary general meeting until September 2, 2024. In accordance with the previously published notice, the extraordinary general meeting was originally intended to be held on August 19, 2024. The Company has postponed the extraordinary general meeting due to administrative reasons. An updated notice for the extraordinary general meeting will be issued shortly.

    Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB

    Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the "Company"), will hold an extraordinary general meeting on 19 August at 14:00 at the Company’s premises at Skiffervägen 48 in Lund.Right to participate and notification Shareholders who wish to participate in the general meeting must: ·be recorded as shareholder in the share register prepared by Euroclear Sweden AB regarding the conditions on the record date of 9 August 2024, and ·notify the Company no later than 13 August 2024. Notification can be made in writing to Phase Holographic Imaging PHI AB,

    Board member Leland Foster resigns due to personal reasons

    Phase Holographic Imaging (PHI), announces the resignation of esteemed board member Leland Foster. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments. After this, the Board of Directors continues to have a quorum in accordance with the Articles of Association."It has been a privilege to be part of Phase Holographic Imaging's journey. The decision to resign was not easy, but I believe it is time for me to retire and focus on personal pursuits. I have full confidence in the Board and Management and look forward to following

    BioStock: PHI aims for US listing

    Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.Read the full article at biostock.se : https://www.biostock.se/2024/07/phi-aims-for-us-listing/ This is a press release from BioStock -

    PHI applies for listing on OTCQB in the United States

    Phase Holographic Imaging (PHI) is pursuing a dual listing on the US-based OTCQB Venture Market (“OTCQB”) to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.PHI's CEO, Patrik Eschricht, comments: "We are excited about the potential of trading on the OTCQB as it offers our current and prospective

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media